Quantum Genesis AI Corp. (: QTZM)

Quantumzyme Corp. is a biotransformation company focused on clean and green chemistry, specializing in the development of engineered enzymes for active pharmaceutical ingredient (API) production. The company leverages novel quantum mechanics, molecular modeling, and engineering approaches to enhance enzyme activity, selectivity, and specificity. Quantumzyme Corp. aims to foster a sustainable society and economy by simplifying complex chemistry and reducing the number of steps in chemical processes. The company's initial product is an enzyme designed for the production of Ibuprofen, targeting select pharmaceutical companies that produce generic drugs. Quantumzyme Corp. is in the process of identifying third-party manufacturers and distributors capable of large-scale production and distribution of its enzyme.

Quantumzyme Corp. generates revenue through the licensing of its engineered enzymes to major API manufacturers and pharmaceutical companies. The company's first developed biocatalyst is intended for use in the manufacturing of Ibuprofen, a widely produced drug. Quantumzyme Corp. plans to generate revenue from technology transfer and royalties as large-scale manufacturing of Ibuprofen API and its use in drug production by pharmaceutical companies increases. The company's business model relies on licensing the rights to use its developed enzymes to large-scale manufacturers and other pharmaceutical companies, with third-party manufacturers responsible for obtaining regulatory approvals and complying with governmental regulatory issues.

• Ibuprofen Enzyme Segment: Quantumzyme Corp.'s initial product is an engineered enzyme designed for the production of Ibuprofen, a widely used API. This segment targets select pharmaceutical companies that produce generic drugs, aiming to make the manufacturing process greener, cost-effective, and more environmentally friendly. The company is in the process of identifying third-party manufacturers and distributors to handle large-scale production and distribution.

Quantumzyme Corp. operates in the dynamic and evolving field of enzyme engineering, which is part of the broader biotechnology sector. The company faces competition from well-established players such as Novozymes, DuPont Industrial Biosciences, BASF, Codexis, and Genencor, which offer a wide range of enzyme products for various industrial applications. Quantumzyme Corp.'s competitive advantages include its focus on clean and green chemistry, the use of novel quantum mechanics and molecular modeling approaches, and its goal to simplify complex chemistry. The company's dedication to its business and scientific principles is expected to be a key differentiator as it ramps up operations. Additionally, Quantumzyme Corp. plans to set up a Scientific Advisory Board with accomplished scientists in the fields of Chemical and Biochemical Engineering and Chemistry to continue advancing its enzyme engineering efforts.

Quantumzyme Corp. caters to pharmaceutical companies, particularly those involved in the production of generic drugs. The company's initial focus is on the manufacturing of Ibuprofen, a widely produced drug, which positions it to serve a broad customer base within the pharmaceutical industry. As the company expands its product offerings, it aims to cater to other sectors such as fragrances, flavors, sustainable materials, plastic degradation, and carbon capture. Quantumzyme Corp.'s customer base is expected to grow as it successfully licenses its engineered enzymes to major API manufacturers and pharmaceutical companies.